Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.

Woo PYM, Ho JMK, Tse TPK, Lam SW, Mak CHK, Chan DTM, Lee MWY, Wong ST, Chan KY, Poon WS.

J Clin Neurosci. 2019 May;63:134-141. doi: 10.1016/j.jocn.2019.01.022. Epub 2019 Jan 31.

PMID:
30712777
2.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
3.

Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.

Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, Vogelbaum MA.

J Neurosurg. 2014 Nov;121(5):1115-23. doi: 10.3171/2014.7.JNS132449. Epub 2014 Sep 5.

PMID:
25192475
4.

Volumetric Analysis Using Low-Field Intraoperative Magnetic Resonance Imaging for 168 Newly Diagnosed Supratentorial Glioblastomas: Effects of Extent of Resection and Residual Tumor Volume on Survival and Recurrence.

Fukui A, Muragaki Y, Saito T, Maruyama T, Nitta M, Ikuta S, Kawamata T.

World Neurosurg. 2017 Feb;98:73-80. doi: 10.1016/j.wneu.2016.10.109. Epub 2016 Oct 29.

PMID:
27989974
5.

Impact of removed tumor volume and location on patient outcome in glioblastoma.

Awad AW, Karsy M, Sanai N, Spetzler R, Zhang Y, Xu Y, Mahan MA.

J Neurooncol. 2017 Oct;135(1):161-171. doi: 10.1007/s11060-017-2562-1. Epub 2017 Jul 6.

PMID:
28685405
6.

Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.

Fujii Y, Muragaki Y, Maruyama T, Nitta M, Saito T, Ikuta S, Iseki H, Hongo K, Kawamata T.

J Neurosurg. 2018 Jul;129(1):1-9. doi: 10.3171/2017.3.JNS162383. Epub 2017 Sep 8.

PMID:
28885120
7.

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.

Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22.

8.

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.

Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC; German Glioma Network.

Ann Oncol. 2013 Dec;24(12):3117-23. doi: 10.1093/annonc/mdt388. Epub 2013 Oct 14.

9.

Which Parameter Is More Important for the Prognosis of New-Onset Adult Glioblastoma: Residual Tumor Volume or Extent of Resection?

Xing Y, Wang X.

World Neurosurg. 2018 Aug;116:e444-e451. doi: 10.1016/j.wneu.2018.05.003. Epub 2018 May 16.

PMID:
29753893
10.

Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy.

Pessina F, Navarria P, Cozzi L, Ascolese AM, Simonelli M, Santoro A, Tomatis S, Riva M, Fava E, Scorsetti M, Bello L.

Ann Surg Oncol. 2016 Sep;23(9):3040-6. doi: 10.1245/s10434-016-5222-3. Epub 2016 Apr 12.

PMID:
27072998
11.

Proliferation-dominant high-grade astrocytoma: survival benefit associated with extensive resection of FLAIR abnormality region.

Jiang H, Cui Y, Liu X, Ren X, Li M, Lin S.

J Neurosurg. 2019 Mar 22:1-8. doi: 10.3171/2018.12.JNS182775. [Epub ahead of print]

PMID:
30901758
12.

An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.

Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW, Ashby LS, Brachman D, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N.

J Neurosurg. 2014 Apr;120(4):846-53. doi: 10.3171/2013.12.JNS13184. Epub 2014 Jan 31.

PMID:
24484232
13.

An extent of resection threshold for newly diagnosed glioblastomas.

Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS.

J Neurosurg. 2011 Jul;115(1):3-8. doi: 10.3171/2011.2.JNS10998. Epub 2011 Mar 18.

PMID:
21417701
14.

When gross total resection of a glioblastoma is possible, how much resection should be achieved?

Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I, Wijesekera O, Olivi A, Rahman M, Quinones-Hinojosa A.

World Neurosurg. 2014 Jul-Aug;82(1-2):e257-65. doi: 10.1016/j.wneu.2014.01.019. Epub 2014 Feb 6.

PMID:
24508595
15.

Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT.

J Neurosurg. 2012 Dec;117(6):1032-8. doi: 10.3171/2012.9.JNS12504. Epub 2012 Oct 5.

PMID:
23039151
16.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R.

Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21.

PMID:
18082451
17.

Evaluation of reproducibility in MRI quantitative volumetric assessment and its role in the prediction of overall survival and progression-free survival in glioblastoma.

Blomstergren A, Rydelius A, Abul-Kasim K, Lätt J, Sundgren PC, Bengzon J.

Acta Radiol. 2019 Apr;60(4):516-525. doi: 10.1177/0284185118786060. Epub 2018 Jul 2.

PMID:
29966430
18.

Automatic estimation of extent of resection and residual tumor volume of patients with glioblastoma.

Meier R, Porz N, Knecht U, Loosli T, Schucht P, Beck J, Slotboom J, Wiest R, Reyes M.

J Neurosurg. 2017 Oct;127(4):798-806. doi: 10.3171/2016.9.JNS16146. Epub 2017 Jan 6.

PMID:
28059651
19.

Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, Hernandez-Hermann M, Gomez L, Ye X, Weingart JD, Olivi A, Blakeley J, Gallia GL, Lim M, Brem H, Quinones-Hinojosa A.

Neuro Oncol. 2014 Jan;16(1):113-22. doi: 10.1093/neuonc/not137. Epub 2013 Nov 26.

20.

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.

Roh TH, Park HH, Kang SG, Moon JH, Kim EH, Hong CK, Ahn SS, Choi HJ, Cho J, Kim SH, Lee SK, Kim DS, Kim SH, Suh CO, Lee KS, Chang JH.

Medicine (Baltimore). 2017 Jul;96(27):e7422. doi: 10.1097/MD.0000000000007422.

Supplemental Content

Support Center